Despite improvement in clinical outcomes observed with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), long-term prognosis remains unfavorable due to the development of either intrinsic or acquired resistance.  Understanding the mechanisms underlying this resistance is vital for designing strategies to address this challenge, and one approach involves the establishment of …Read More >

WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses generated by iMN041, a prodrug of a DNA methyl transferase/ribonucleotide reductase inhibitor.  This study also assessed the efficacy of iMN041 in mouse xenografts of human clear cell renal cell cancer, pancreatic cancer, and triple negative …Read More >

The recent publication in the journal Organic Letters, ‘DNA-Compatible Cyclization Reaction to Access 1,3,4-Oxadiazoles & 1,2,4-Triazoles‘ by our WuXi Biology DEL team, introduces two novel DNA-compatible reactions, successfully incorporating bioactive cores 1,3,4-oxadiazoles and 1,2,4-triazoles into the DEL library. These cores are reported to show broad ranges of biological activities, such as antiviral, anti-inflammatory, anticancer, antifungal, …Read More >

The EML4-ALK fusion gene occurs in approximately 5% of non-small-cell lung cancers (NSCLCs), making this oncogene an important drug target.  The development of ALK tyrosine kinase inhibitors (ALK-TKIs) has been a major advance in treating NSCLC with this fusion gene, but acquired resistance to ALK-TKIs ultimately limits their use.  To support the development of next-generation …Read More >

High-dimensional (HD) flow cytometry allows researchers to perform deep phenotyping of immune cells at the single cell level with increased accuracy and sensitivity.  This technology enables complex pathway characterization and data integration for the identification of biomarkers used in immunotherapy.  WuXi AppTec offers a comprehensive panel of HD flow cytometry services, with more than 100 …Read More >

The contribution of the X-ray crystallography team from our WuXi AppTec site in Germany was acknowledged in a recent study published in the journal Cancer Discovery. In this study, the authors show that compound STX-478, an allosteric PI3Kα inhibitor, selectively targets prevalent PI3Kα helical- and kinase-domain mutant tumors. STX-478 demonstrated robust efficacy in human tumor …Read More >

OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our FaDu ATM KO tumor model. Introduction: As reported, several physiological processes, such as the production of reactive oxygen species during …Read More >

Due to the special configuration of the DNA encoded library (DEL), each DEL molecule carries a DNA sequence encoding its identity through a bifunctional linker. The linkers that are considered “redundant” and “troublesome” in traditional drug discovery actually offer innate advantages in many application scenarios. In this article, we review how to utilize DNA-encoded libraries …Read More >

We offer established protocols for cryo-EM structure determination, with extensive experience in epitope mapping, formulation characterization, and structure-based drug discovery (SBDD). Our integrated services platform also includes: Biophysical and biochemical screening assays Crystal-grade protein production High-resolution X-ray crystallography